Save on Durvalumab with Coupons, Discounts & Savings Programs

Durvalumab is available in the following:

• 500 mg/10 mL (50 mg/mL) solution in a single-dose vial
• 120 mg/2.4 mL (50 mg/mL) solution in a single-dose vial

Durvalumab is a PD-L1 inhibitor that is used to treat:

Non-small cell lung cancer (NSCLC):

• Advanced NSCLC, after platinum-based chemotherapy and radiation
• Metastatic NSCLC without EGFR or ALK mutations, together with Imjudo (tremelimumab) and platinum-based chemotherapy
• Extensive-stage SCLC together with platinum-based chemotherapy
• Locally advanced or metastatic biliary tract cancer, together with gemcitabine (Gemzar) and cisplatin (Platinol)
• Advanced liver cancer together with Imjudo (tremelimumab)

Durvalumab is an immune checkpoint inhibitor (immunotherapy) that blocks PD-L1. By blocking PD-L1, it takes the “brakes” off the immune system to detect and attack the cancer.

Your Durvalumab dose and schedule will depend on your cancer type. Depending on your cancer type, you might also receive other medications, like Imjudo (tremelimumab) and/or chemotherapy as part of your treatment plan.

For adults weighing 66 lbs or more:

• Advanced non-small cell lung cancer (NSCLC): The typical dose is 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks as an infusion through the vein (IV). The maximum treatment time is 1 year
• Metastatic NSCLC: The typical dose is 1,500 mg every 3 weeks for 4 cycles, then 1,500 mg every 4 weeks as an infusion through the vein (IV)
• Small cell lung cancer (SCLC): The typical dose is 1,500 mg every 3 weeks for 4 cycles, then 1,500 mg every 4 weeks as an infusion through the vein (IV)
• Biliary tract cancers: The typical dose is 1,500 mg every 3 weeks for up to 8 cycles, then 1,500 mg every 4 weeks as an infusion through the vein (IV)
• Liver cancers: The typical dose is 1,500 mg every 4 weeks as an infusion through the vein (IV)

Your dose will be different if your body weight is less than 66 lbs.

Durvalumab is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Durvalumab:

• Higher blood sugar levels
• Lower blood calcium levels
• Lower white blood cell counts
• Cough
• Higher liver lab tests
• Trouble breathing and symptoms of lung inflammation
• Feeling very tired
• Lower blood sodium levels
• Higher blood potassium levels
• Sore throat, runny nose, and other symptoms of colds and sinus infections
• Trouble catching your breath
• Rash

Serious side effects are rare with Durvalumab. Contact your healthcare provider immediately if you experience any of the following. Immune-related adverse events: diarrhea, stomach pain or cramps, blood or mucus in stool, rash, cough, trouble breathing Infusion-related reactions: shortness of breath, itching, chills, flushing, chest discomfort

There are no major drug interactions listed for Durvalumab. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Various FDA-approved generic manufacturers

Durvalumab can harm your unborn baby. If you are able to
become pregnant, you should use an effective method of birth control during your treatment and for at least 3 months after the last dose of Durvalumab. Talk to your healthcare provider about birth control methods that you can use during this time. Tell your healthcare provider right away if you become
pregnant during treatment with Durvalumab.

• Imfinzi